covid,-the-merck-antiviral-in-italy-from-4-january:-who-does-it-go-to-and-how-much-it-costs-–-rb

Covid, the Merck antiviral in Italy from 4 January: who does it go to and how much it costs – RB

Covid, the Merck antiviral in Italy from 4 January: to whom it goes and how much it costs – RB

Hello, Welcome to the RockedBuzz News site! I will present you all the details of Covid, the Merck antiviral in Italy from 4th January: to whom it goes and how much it costs – RB here.

Covid, the Merck antiviral in Italy from 4 January: who it goes to and how much it costs – RB

Covid, the Merck antiviral in Italy from 4 January: to whom it goes and how much it costs – RB We have explained the details of the news, step by step, below. Covid, the Merck antiviral in Italy from 4 January: to whom it goes and how much it costs – RB Keep reading our news. Here are all the details on the subject.

Covid, the Merck antiviral in Italy from 4 January: who does it go to and how much it costs – RB

Merck & Co. (also known by the name Merck Sharp & Dohme or by the acronym MSD) is a of the largest pharmaceutical companies in the world. Founded in the United States in the distant 1891, today it has its headquarters in Readington, a small town in New Jersey. During the last two years, the company has risen to prominence in the news all over the world for the numerous trials in the fight against the coronavirus.

In recent days, positive news has come in this regard. Merck’s new anti-Covid pill will begin to be distributed in Italy as well from the next January 4 . This was announced by AIFA, the Italian Medicines Agency, that last 22 December 2021 approved the use of this drug in emergency conditions .

The antiviral produced by MSD is called Molnupiravir (although the common name under which it will be found on the market is Lagevrio ). According to tests carried out during the last twelve months, the medicine is expected to prevent beyond 30 % of severe cases and hospitalizations among those who test positive for the virus: this, however, in the event that the drug is taken immediately after the infection.

Covid, Merck antiviral pill: a home cure

During the same session of the works, the technical-scientific committee of Aifa (based in via del Tritone in Rome) also approved the use of Remdesivir , another antiviral drug that has in fact already been used in the United States since the outbreak began. Unlike the latter, which must be administered by intravenous infusion (therefore in a hospital) with a treatment lasting 3 days, Molnupiravir has the advantage that it can be taken at home , being distributed in tablets.

This is the first drug developed specifically to combat Covid – 19 (although in the first studies, dating back to about a decade ago , it was created because it was thought that it could fight the flu): only a few months after the outbreak of the pandemic it was in fact hailed as a turning point in the fight against the coronavirus . However, its effectiveness, which at the beginning was given to 50%, has been reduced to 30%. To the point that France , which had already purchased 50 thousand cycles, retraced her steps and gave up the drug.

Covid , Merck antiviral pill: how and who can take it

Molnupiravir will be reserved for patients over the 18 years of age with risk which suggest an aggravation. It should be taken within 5 days of the onset of symptoms , otherwise its use risks becoming useless. In fact, its role is to hinder the replication of the virus in the body, which occurs in the early stages of the infection.

The drug, explains Aifa, ‚Äúproduces alterations in the genetic material (Rna) of the virus during replication, making it unable to multiply. This is expected to reduce the need for hospitalization of patients who also contract the new variants of Covid – 19 “. The duration of the treatment is set at 5 days .

The intake of Molnupiravir consists of the ingestion of 4 tablets twice a day . The cost of a cycle – at least on the American market – is approximately 700 dollars (equivalent to just over 615 EUR). The drug will be distributed to the Regions from next January 4 by the commissioner of General Figliuolo. All patients who take it will be registered in a special monitoring register to verify its short and long-term effects .